Impact of comorbidities in the response of atopic patients treated with dupilumab: a real‐life study up to 36 weeks-Reference-Cited by-同舟云学术

Impact of comorbidities in the response of atopic patients treated with dupilumab: a real‐life study up to 36 weeks

Published:2022-07-26 Issue:12 Volume:36 Page:
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:Acad Dermatol Venereol

Author:

Mastorino L.¹^ORCID,Cantafio Duò V.L.¹,Vecco C.¹,Gelato F.¹,Giordano S.¹,Roccuzzo G.¹,Cavaliere G.¹,Avallone G.¹,Ortoncelli M.¹,Ribero S.¹^ORCID,Quaglino P.¹^ORCID

Affiliation:

1. Department of Medical Sciences, Dermatologic Clinic University of Turin Turin Italy

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.18427

Reference10 articles.

1. Guidelines of care for the management of atopic dermatitis

2. Dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitis

3. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in adult cohort: a real‐life Italian tertiary centre experience

4. Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma

5. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between systemic immune-inflammation index and atopic dermatitis: a cross-sectional study of NHANES 2001–2006;Frontiers in Medicine;2024-08-29

2. Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents;Expert Opinion on Biological Therapy;2024-06-25

3. A Review of Dupilumab in the Treatment of Atopic Dermatitis in Infants and Children;Drug Design, Development and Therapy;2024-03

4. Altered Gene Expression of IL-35 and IL-36α in the Skin of Patients with Atopic Dermatitis;International Journal of Molecular Sciences;2023-12-28

5. Two Cases of Immune Drift Phenomena Caused by Biologic Agents for Treating Psoriasis and Atopic Dermatitis;Clinical, Cosmetic and Investigational Dermatology;2023-12